for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Neuca SA

NEUP.WA

Latest Trade

372.00PLN

Change

6.00(+1.64%)

Volume

914

Today's Range

367.00

 - 

372.00

52 Week Range

229.00

 - 

389.00

As of on the Warsaw Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
366.00
Open
370.00
Volume
914
3M AVG Volume
0.03
Today's High
372.00
Today's Low
367.00
52 Week High
389.00
52 Week Low
229.00
Shares Out (MIL)
4.36
Market Cap (MIL)
1,619.54
Forward P/E
15.89
Dividend (Yield %)
1.80

Next Event

Neuca SA Annual Shareholders Meeting

Latest Developments

More

Neuca Q3 Net Profit Up At 28.0 Mln Zlotys

Neuca Resolves To Merge With Wholly-Owned ACP Pharma

Neuca Q2 Net Profit Up At 28.8 Mln Zlotys

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Neuca SA

Neuca SA is a Poland-based company engaged in the healthcare sector. The Company’s main activities comprise the wholesale of pharmaceuticals; running its own pharmacies under the brand name Synoptis Pharma; provision of advertising, marketing and information technology (IT) services to healthcare market, production of pharmaceuticals and other pharmaceutical products, partnership programs for independent pharmacies, as well as sales of clothes and road cargo transport. In addition, Neuca SA provides transport and logistics services. Furthermore, It provides clinical studies for drug's safety and efficiency. It is also engaged in medical research by testing and developing diabetes measuring equipment. The Company operates a number of subsidiaries, such as ACP Pharma SA, Przychodnia Rejonowa Numer 3 Eskulap Zespol Lekarzy Rodzinnych Sp z o o, Medica Pro Familia, Medic Klinika Sp z o o, Ortopedio.pl Sp z o o and Niepubliczny Zaklad Opieki Zdrowotnej ,,Wola-Med'' Sp z o o.

Industry

Biotechnology & Drugs

Contact Info

ul. Szosa Bydgoska 58

+48.56.6694000

https://www.neuca.pl/

Executive Leadership

Kazimierz Michal Herba

Chairman of the Supervisory Board

Piotr Sucharski

General Director, Chairman of the Management Board

Wieslawa Teresa Herba

Vice Chairman of the Supervisory Board

Grzegorz Dzik

Vice Chairman of the Management Board, Finance Director

Pawel Kusmierowski

Vice Chairman of the Management Board

Key Stats

2.50 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, PLN)

2017

7.5K

2018

7.8K

2019(E)

8.1K
EPS (PLN)

2016

22.030

2017

19.100

2018

19.340

2019(E)

23.032
Price To Earnings (TTM)
14.77
Price To Sales (TTM)
0.20
Price To Book (MRQ)
2.41
Price To Cash Flow (TTM)
9.65
Total Debt To Equity (MRQ)
80.25
LT Debt To Equity (MRQ)
23.49
Return on Investment (TTM)
16.16
Return on Equity (TTM)
3.77

Latest News

Latest News

BRIEF-Neuca Q3 Net Profit Up At 28.0 Mln Zlotys

* REPORTED ON TUESDAY Q3 NET PROFIT 28.0 MILLION ZLOTYS VERSUS 25.6 MILLION ZLOTYS YEAR AGO

BRIEF-Neuca Q2 Net Profit Up At 28.8 Mln Zlotys

* Q2 NET PROFIT 28.9 MILLION ZLOTYS VERSUS 15.6 MILLION ZLOTYS YEAR AGO

BRIEF-Neuca Plans To Buy Back Up To 150,000 Shares

* SAYS IT LAUNCHES OFFER TO BUY BACK UP TO 150,000 SHARES EQUAL TO 3.3% STAKE IN ITS SHARE CAPITAL AT 302 ZLOTYS PER SHARE

BRIEF- NEUCA Q1 Net Profit Up At 36.3 Mln Zlotys

* REPORTS Q1 NET PROFIT OF 36.3 MILLION ZLOTYS VERSUS 31.2 MILLION ZLOTYS YEAR AGO

BRIEF-Neuca FY Net Profit Up At 98.3 Mln ZLOTYS

* FY NET PROFIT OF 98.3 MILLION ZLOTYS VERSUS 94.1 MILLION ZLOTYS YEAR AGO

BRIEF-Neuca Receives Notice From Tax Office Regarding 2012 Tax Payment

* SAYS IT RECEIVED DECISION OF HEAD OF CUSTOMS AND TAX OFFICE IN TORUN DETERMINING THE TAX LIABILITY IN INCOME TAX FORM 2012 IN THE AMOUNT OF 7.7 MLN ZLOTYS PLUS DUE INTEREST

BRIEF-Neuca Offers To Buy Back 150,000 Of Own Shares

* OFFERS TO BUY BACK NO MORE THAN 150,000 OF CO'S SHARES REPRESENTING 3.24 PCT OF ITS SHARE CAPITAL FOR 235 ZLOTYS/SHARE

BRIEF-Neuca Q3 Net Profit Up At 24.1 Mln Zlotys

* REPORTS Q3 NET PROFIT OF 24.1 MLN ZLOTYS VS 21.7 MLN ZLOTYS YEAR AGO

BRIEF-Neuca Q2 Net Profit Rises To 18.5 Mln Zlotys

NEUCA SA: * Q2 NET PROFIT 18.5 MLN ZLOTYS VS 11.8 MLN ZLOTYS YEAR AGO * Q2 REVENUE 1.78 BLN ZLOTYS VS 1.78 BLN ZLOTYS YEAR AGO * Q2 OPER PROFIT 24.8 MLN ZLOTYS VS 16.1 MLN ZLOTYS YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Neuca Q1 Net Profit Up At 31.8 Million Zlotys

* Q1 NET PROFIT 31.8 MILLION ZLOTYS VERSUS 30.2 MILLION ZLOTYS YEAR AGO

BRIEF-Neuca Plans To Merge With Its Two Wholly Owned Units

* PLANS TO MERGE WITH ITS TWO WHOLLY OWNED UNITS, HURTOWNIA APTEKARZY GALENICA-PANAX AND UNNA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Neuca Buys 100 Pct Shares In Clinmed Pharma

* CLINMED PHARMA DEALS WITH CLINICAL TESTS OF MEDICAL PRODUCTS AND ONCOLOGY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Neuca FY Net Profit Down At 94.1 Million Zlotys

* FY REVENUE 7.49 BILLION ZLOTYS VERSUS 7.08 BILLION ZLOTYS YEAR AGO

BRIEF-Neuca Unit Buys „Twoje Centrum Medyczne” In Belchatow

* ITS UNIT NEUCA MED SP. Z O.O. BUYS 100% STAKE IN „TWOJE CENTRUM MEDYCZNE” SP. Z O.O. IN BELCHATOW

BRIEF-Neuca Plans To Incorporate Its Two Wholly Owned Units

* PLANS TO INCORPORATE ITS TWO WHOLLY OWNED UNITS PREGO SA AND MULTI SP. Z O.O. Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Neuca Q3 net profit down at 21.7 mln zlotys

* Q3 REVENUE 1.81 BILLION ZLOTYS VERSUS 1.70 BILLION ZLOTYS A YEAR AGO

BRIEF-Neuca plans to incorporate its wholly owned unit ILC Sp. z o.o.

* PLANS TO INCORPORATE ITS WHOLLY OWNED UNIT ILC SP. Z O.O. Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Neuca to take over Itero-Silfarm

* PLANS TO TAKE OVER 100 PERCENT OF ITERO-SILFARM SP. Z O.O. BY TRANSFERRING ENTIRE ASSETS OF THE ACQUIRED COMPANY TO NEUCA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Neuca Q2 net profit decreases to 11.8 mln zlotys

* Q2 REVENUE 1.78 BILLION ZLOTYS VERSUS 1.67 BILLION ZLOTYS YEAR AGO

BRIEF-Neuca sees FY 2017 net profit at level of 100 mln zlotys

* SEES FY 2017 NET PROFIT AT LEVEL OF 100 MILLION ZLOTYS VERSUS PREVIOUSLY FORECASTED FY 2017 NET PROFIT OF 115 MILLION ZLOTYS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up